For peptide cancer vaccines to be effective, they must contain both CD8+ and CD4+ epitopes to activate cytotoxic T lymphocytes (CTL) anti-tumor immunity and T helper cell activation to sustain the CTLs effector function (8). This evidence concerns the gene CD8A and neoplasm.